To understand if SMARCA4 alterations were associated with differences in clinical prognosis, we performed a retrospective study of a deidentified database of advanced diagnosis NSCLC patients (stage 3B+) treated in the Flatiron Health network between January 2011 and June 2017 who underwent FoundationOne® or FoundationOne® CDx tumor sequencing as part of routine clinical care. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.